✓ Plata cu cardul restabilită — finalizare securizată prin Privacy Shield

Calutide

Calutide (Bicalutamide 50 mg) — Cipla non-steroidal anti-androgen for advanced prostate cancer. Combined with LHRH agonist for combined androgen blockade. Hepatotoxicity monitoring.

Verificat medical de Morgan Ellis — Cercetător farmaceutic · 8 ani de experiență  · Ultima recenzie: mai 2026

Plată criptată
Plățile în crypto reduc prețul cu 10%
Livrare discretă în întreaga lume
1.400+ clienți · 50+ țări

Acest produs este momentan indisponibil și nu poate fi comandat.

Răspuns rapid

Calutide — Bicalutamide 50 mg (Cipla Inc). Non-steroidal androgen receptor antagonist for advanced prostate cancer — usually combined with LHRH agonist/antagonist for combined androgen blockade, or as monotherapy in selected cases.

Ce beneficii oferă MedsBase:

  • producător certificat WHO-GMP
  • Ambalaj discret în plic simplu
  • Livrare în toată lumea
  • Evaluat de peste 1.400 de clienți (citește recenziile)

📦 Garanția de retransmitere: dacă comanda dvs. nu a ajuns în 20 de zile lucrătoare de la expediere, o retransmitem fără costuri suplimentare. Citește politica.

De ce să comanzi de la MedsBase

Calutide ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.

⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.

Hepatotoxicity
Bicalutamide can cause severe hepatic injury. Baseline LFTs; recheck at 1 month and every 3 months in the first year. Stop immediately if jaundice, dark urine, or pruritus develops or LFTs >2.5× ULN.

Întrebări frecvente

When is this used?

Non-steroidal androgen receptor antagonist for advanced prostate cancer — usually combined with LHRH agonist/antagonist for combined androgen blockade, or as monotherapy in selected cases.

Side effects to watch?

Hot flushes, gynaecomastia, fatigue, sexual dysfunction (anti-androgen class effect). Drug-specific monitoring as outlined in the safety boxes above.

Interacțiuni medicamentoase?

Vary by molecule — abiraterone is CYP3A4 substrate; bicalutamide is CYP3A4 substrate. Always disclose all medications. Strong CYP3A4 inhibitors/inducers significantly affect levels.

When should it be stopped?

On disease progression, intolerable toxicity, or successful response with planned treatment break. Always specialist-decided — abrupt cessation can result in transient PSA rise (withdrawal response) which is generally not concerning.

PSA monitoring?

PSA every 1-3 months while on therapy. Rising PSA on castration suggests castration-resistance — may need switch to second-line agents (abiraterone, enzalutamide, docetaxel).

Combined androgen blockade?

LHRH agonist (goserelin, leuprolide) + bicalutamide is a common combination. Maximal androgen blockade has modest survival benefit over LHRH alone.

Bone health?

Long-term androgen deprivation accelerates bone loss. Add a bisphosphonate (zoledronic acid) or denosumab in osteopenia/osteoporosis. Calcium and vitamin D supplementation.

Sarcină?

Anti-androgens are teratogenic — partners must use effective contraception during therapy. Most relevant for younger men with localised disease.

Ce fac dacă uit o doză?

Take when you remember if same day; otherwise skip. Specialist may have specific guidance for missed doses depending on regimen.

Cardiovascular monitoring?

Mandatory for fosfestrol; advised for abiraterone (BP, fluid retention, electrolytes); routine for bicalutamide (occasional CV review).

Other Cancer & Anti-Androgen Therapy

  • Calutide — bicalutamide 50 mg — alternative anti-androgen brand
  • Xbira — abiraterone 250 mg — CYP17 inhibitor for mCRPC
  • Honvan — fosfestrol 120 mg — diethylstilbestrol diphosphate
  • Estramustine — estramustine phosphate — alkylator for hormone-refractory disease
  • Zoldria — zoledronic acid IV for bone metastases
Disclaimer medical: Cancer therapy is highly individualised. Specific drug, dose, schedule, monitoring, and supportive care must be determined by a qualified oncologist or haematologist based on tumour biology, staging, comorbidities, and goals of care. This information is educational; it does not substitute for professional medical advice.

More options in Anti Cancer Medication

Clasificate în funcție de volumul recent de comenzi MedsBase — ce aleg alți clienți în această categorie.

Concentrație

50 mg

Cantitate

30 Comprimate/s, 60 Comprimate/s, 90 Comprimate/s

Formă farmaceutică

Comprimat/e

Producător

Cipla Inc

Indicație

Prostate Cancer

Brand generic

Bicalutamide

Recenzii

Nu există recenzii încă

Adăugați o recenzie
Calutide Calutide
Evaluare*
0/5
* Evaluarea este obligatorie
* Răspunsul este obligatoriu
Recenzia dvs.
* Recenzia este obligatorie
Nume
* Numele este obligatoriu
Adăugați fotografii sau videoclip la recenzia dvs.

Întrebări și răspunsuri

Pune o întrebare
Calutide Calutide
Întrebarea ta
* Întrebarea este obligatorie
Nume
* Numele este obligatoriu
Nu există întrebări încă